216 related articles for article (PubMed ID: 33309691)
41. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
42. Clinical Trials in Branch Retinal Vein Occlusion.
Panakanti TK; Chhablani J
Middle East Afr J Ophthalmol; 2016; 23(1):38-43. PubMed ID: 26957837
[TBL] [Abstract][Full Text] [Related]
43. Coming of Age: Biosimilars.
Kiss S; Fine HF; Krawitz J
Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):162-165. PubMed ID: 29554382
[No Abstract] [Full Text] [Related]
44. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
45. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
Vottonen P
Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
[No Abstract] [Full Text] [Related]
46. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
[TBL] [Abstract][Full Text] [Related]
47. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
48. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
49. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
[TBL] [Abstract][Full Text] [Related]
50. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
Wood EH; Karth PA; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
[TBL] [Abstract][Full Text] [Related]
51. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
Chae JB; Rho CR; Shin JA; Lyu J; Kang S
Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
[TBL] [Abstract][Full Text] [Related]
52. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
[No Abstract] [Full Text] [Related]
53. Updates on the Clinical Trials in Diabetic Macular Edema.
Demirel S; Argo C; Agarwal A; Parriott J; Sepah YJ; Do DV; Nguyen QD
Middle East Afr J Ophthalmol; 2016; 23(1):3-12. PubMed ID: 26957834
[TBL] [Abstract][Full Text] [Related]
54. Approved pharmacotherapy for myopic choroidal neovascularization: a review of randomized controlled trials in ranibizumab and aflibercept.
Wang JK; Huang TL; Su PY; Chang PY
Eye Sci; 2015 Dec; 30(4):198-200. PubMed ID: 27215011
[TBL] [Abstract][Full Text] [Related]
55. Anti-Vascular Endothelial Growth Factor Therapy in Pregnancy: What We Know, What We Don't Know, and What We Don't Know We Don't Know.
Peracha ZH; Rosenfeld PJ
Retina; 2016 Aug; 36(8):1413-7. PubMed ID: 27388726
[No Abstract] [Full Text] [Related]
56. Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries.
Thakore RV; Greenberg PB; Behrens JJ; French DD
JAMA Ophthalmol; 2016 Sep; 134(9):1071-2. PubMed ID: 27366859
[No Abstract] [Full Text] [Related]
57. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
58. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
59. The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.
Danyliv A; Glanville J; McCool R; Ferreira A; Skelly A; Jacob RP
Adv Ther; 2017 Mar; 34(3):611-619. PubMed ID: 28188433
[TBL] [Abstract][Full Text] [Related]
60. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
Silver J
JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
